Chemical Works of Gedeon Richter (RIG2) Stock Price & Analysis
RIG2 Stock Chart & Stats
- Day’s Range
- EUR 35.54 - EUR 36.14
- 52-Week Range
- EUR 24.60 - EUR 37.02
- Previous Close
- EUR 35.34
- Volume
- 0
- Average Volume (3M)
- 121
- Market Cap
- EUR 6.44B
- Enterprise Value
- EUR 1.94T
- Total Cash (Recent Filing)
- EUR 136.62B
- Total Debt (Recent Filing)
- EUR 21.74B
- Price to Earnings (P/E)
- 10.3
- Beta
- 0.57
- Next Earnings
- Nov 10, 2026 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 5.15%
Chemical Works of Gedeon Richter News
RIG2 FAQ
What was Chemical Works of Gedeon Richter’s price range in the past 12 months?
What is Chemical Works of Gedeon Richter’s market cap?
When is Chemical Works of Gedeon Richter’s upcoming earnings report date?
How were Chemical Works of Gedeon Richter’s earnings last quarter?
Is Chemical Works of Gedeon Richter overvalued?
Does Chemical Works of Gedeon Richter pay dividends?
What is Chemical Works of Gedeon Richter’s EPS estimate?
How many shares outstanding does Chemical Works of Gedeon Richter have?
What happened to Chemical Works of Gedeon Richter’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Chemical Works of Gedeon Richter?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Chemical Works of Gedeon Richter
Chemical Works of Gedeon Richter Plc engages in the development and manufacture of pharmaceuticals. The firm focuses on central nervous system, women's healthcare, cardiovascular, and OTC products. It operates through the following segments: Neuropsychiatry (CNS), General Medicines (GM), Women’s Healthcare (WHC), Biotechnology (BIO), and Pharma Other. The CNS segment focuses on building a pipeline of small molecule drug candidates mainly in the field of neuropsychiatry. The GM segment includes a traditional and generic portfolio in various therapeutic areas in the Central and Eastern European regions. The WHC segment provides pharmaceutical products for European women. The BIO segment is involved in its biotechnology platform to develop and manufacture biosimilar drugs for global markets. The Pharma Other segment relates to the remaining wholesale and retail business of the Group and all other activities. The company was founded by Gedeon Richter in 1901 and is headquartered in Budapest, Hungary.
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Gabor Orban
- Employees
- 11,955
- Website
- www.gedeonrichter.com
- Address
- Gyömrői út 19-21, Budapest, BU, 1103, HU
Chemical Works of Gedeon Richter (RIG2) Earnings & Revenues
RIG2 Company Deck
RIG2 Earnings Call
Earnings Call SentimentPositive
The earnings call presented strong underlying operational progress: solid constant-currency revenue growth (8.7%), a significant 21% rise in Clean EBIT on a constant-currency basis, robust biotech and CNS performance, record free cash flow, and measurable cost/ESG benefits from API consolidation. However, reported results were meaningfully impacted by FX losses (notably >HUF 32bn in Q2), a weaker General Medicines performance affected by timing and market factors, one-off impairments in Biotech, and restructuring costs. On balance, the operational wins, upgraded Clean EBIT guidance, cash generation and pipeline progress outweigh the transitory negatives driven largely by FX and one-off items, supporting a constructive outlook.
View all DE:RIG2 earnings summariesRIG2 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 5 | 2 |
| Technical Analysis | 4 | 5 | 1 |
| Moving Averages | 11 | 0 | 1 |